Starting in July, Medicare beneficiaries may be able to get a GLP-1 prescription for weight loss for $50 a month. It’s a ...

Blockbuster weight-loss drugs may be doing more than shrinking waistlines—they could be slowing cancer, too. Four ...

The world’s most popular weight-loss and diabetes drugs are linked to a powerful new possible benefit: better outcomes for ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative. The trial is ...

Led by the renowned bariatric surgeon Dr. Amit Taggar, the family-owned practice marks one year of patient-centered, advanced weight loss surgery in Tampa, FL. At TWLI, patients are treated like ...

GLP-1 receptor agonists (GLP-1 RAs) produced meaningful weight loss in patients with cirrhosis. Although those with compensated disease did not face notable muscle loss, those with decompensated ...

Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...

The U.S. Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and long ...